Choledocholithiasis — management
CBD stones · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Common bile duct stones risk cholangitis and gallstone pancreatitis; risk-stratified using clinical, biochemical and imaging predictors to select ERCP, and most patients proceed to cholecystectomy to prevent recurrence.
Red flags
- Fever, rigors and jaundice (cholangitis)
- Hypotension/septic shock
- Features of gallstone pancreatitis
- Altered mental status (Reynolds pentad)
Assessment
Differential diagnosis
- Ascending cholangitis
- Gallstone pancreatitis
- Malignant biliary obstruction
- Mirizzi syndrome
- Benign biliary stricture
- Primary sclerosing cholangitis
Investigations
- LFTs (cholestatic pattern, rising bilirubin/ALP)
- FBC, CRP, amylase/lipase, coagulation
- Transabdominal ultrasound (duct dilatation, stones)
- MRCP or EUS for intermediate-probability stones
- ERCP as therapeutic confirmation in high-probability cases
Management
- Assess for cholangitis (fever, jaundice, RUQ pain) and pancreatitis — these change urgency
- Stratify CBD stone probability using bilirubin, duct diameter on ultrasound and clinical features
- High probability: proceed to ERCP with sphincterotomy and stone extraction
- Intermediate probability: image further with MRCP or EUS before ERCP
- Low probability: proceed to cholecystectomy with on-table cholangiogram or expectant management
- Treat cholangitis with resuscitation, antibiotics and urgent biliary drainage
- Clear the duct endoscopically; place a stent if the duct cannot be fully cleared at first attempt
- Arrange laparoscopic cholecystectomy (ideally during the same admission) to prevent recurrence
- Consider single-stage laparoscopic bile duct exploration where expertise exists
- Correct coagulopathy before sphincterotomy and monitor for post-ERCP pancreatitis
- Follow up to confirm LFT normalisation and completed cholecystectomy
Drugs & doses
Piperacillin-tazobactam 4.5 g IV three–four times daily (if cholangitis)
Co-amoxiclav 1.2 g IV three times daily (alternative)
Rectal diclofenac/indomethacin 100 mg PR at ERCP (post-ERCP pancreatitis prophylaxis)
Analgesia and IV fluids as required
Disposition
Admit for ERCP and early cholecystectomy; urgent biliary drainage if cholangitis.
Complications & pitfalls
- Ascending cholangitis and sepsis
- Gallstone pancreatitis
- Post-ERCP pancreatitis, bleeding or perforation
- Retained/recurrent stones
- Biliary stricture
Exam pearls
- A dilated CBD with a high/rising bilirubin on ultrasound makes stones highly likely — go straight to ERCP
- Use MRCP or EUS to avoid unnecessary diagnostic ERCP in intermediate-risk patients
- Same-admission cholecystectomy after ductal clearance reduces recurrent biliary events
- Rectal NSAID at ERCP lowers the risk of post-ERCP pancreatitis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.